| abstract |
By administering to a patient a pharmaceutically acceptable amount of a thienotriazolodiazepine compound of formula (1) or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof in a mammal. Treatment of small cell lung cancer: [Wherein, R 1 represents alkyl having 1 to 4 carbon atoms, and R 2 represents a hydrogen atom; a halogen atom; or 1 to 4 carbon atoms which may be substituted with a halogen atom or a hydroxyl group. R 3 is a halogen atom; a halogen atom, an alkyl having 1 to 4 carbon atoms, an alkoxy having 1 to 4 carbon atoms, or phenyl optionally substituted with cyano; —NR 5 — ( CH 2 ) m —R 6 (wherein R 5 is a hydrogen atom or alkyl having 1 to 4 carbon atoms, m is an integer of 0 to 4, and R 6 is substituted with a halogen atom) Or —NR 7 —CO— (CH 2 ) n —R 8 (wherein R 7 is a hydrogen atom or alkyl having 1 to 4 carbon atoms, n is an integer of 0 to 2, R 8 A phenyl or pyridyl optionally substituted by halogen atom), and, R 4 is -. (CH 2) in a -CO-NH-R 9 (wherein, a is an integer of from 1 to 4 R 9 is alkyl having 1 to 4 carbon atoms; hydroxyalkyl having 1 to 4 carbon atoms; alkoxy having 1 to 4 carbon atoms; or alkyl having 1 to 4 carbon atoms; 4 is an alkoxy having 4 carbon atoms, phenyl or pyridyl which may be substituted with an amino or hydroxyl group.) Or — (CH 2 ) b —COOR 10 (wherein b is an integer of 1 to 4) , R 10 is alkyl having 1 to 4 carbon atoms. ]. [Selection] Figure 1 |